Rocío
Aller De La Fuente
Hospital Universitario de Donostia
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (6)
2024
-
Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)
Hepatology
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2022
-
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Hepatology, Vol. 76, Núm. 4, pp. 1121-1134
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology